華檢醫療(01931.HK)預計年度純利減少不多於55%
格隆匯 2 月 3日丨華檢醫療(01931.HK)公佈,預期截至2020年12月31日止年度集團將錄得大致上與截至2019年12月31日止年度的金額相若的收入;集團母公司擁有人應占溢利將較截至2019年12月31日止年度減少不多於55%;及集團母公司擁有人應占經調整溢利將較截至2019年12月31日止年度減少不多於50%。
報吿期間的集團母公司擁有人應占溢利減少主要由於就公司於2019年1月收購威士達醫療有限公司60%股權重新計量先前持有的威士達權益而產生的一次性非經營性收益,反映於截至2019年12月31日止年度的集團母公司擁有人應占溢利,但報吿期間的集團母公司擁有人應占溢利並無本項收益及中國內地為應對2020年初爆發新型冠狀病毒疫情所實施的關閉醫院及其他檢疫和社交隔離措施,導致終端客户對體外診斷("IVD")產品的需求暫時下降,從而對集團IVD產品分銷業務的盈利能力造成不利影響。上文因素(i)被反映於截至2019年12月31日止年度的集團母公司擁有人應占溢利而報吿期間並不存在的以下各項所部分抵銷:(a)一次性非經營性按公允價值計入損益的金融負債公允價值虧損;(b)與收購事項有關的一次性存貨公允價值調整變現開支及(c)首次公開發售開支。報吿期間的集團母公司擁有人應占經調整溢利減少主要由於如上文第(ii)項所述COVID-19對集團IVD產品分銷業務盈利能力的不利影響。集團正密切審視市場情況,對業務戰略和營運作出調整從而儘量減少有關負面影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.